<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00768859</url>
  </required_header>
  <id_info>
    <org_study_id>M08TRA</org_study_id>
    <secondary_id>2008-000987-18</secondary_id>
    <nct_id>NCT00768859</nct_id>
  </id_info>
  <brief_title>Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study</brief_title>
  <acronym>TRAIN</acronym>
  <official_title>Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the activity of the combination of paclitaxel, trastuzumab and carboplatin as
      neo-adjuvant treatment in patients with stage II or III HER2 positive breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response (pCR) rate at surgery</measure>
    <time_frame>at the completion of neo-adjuvant chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe disease-free and overall survival</measure>
    <time_frame>during routine follow up visits after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Breast Cancer</condition>
  <condition>HER2 Positive</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel, trastuzumab and carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel, trastuzumab and carboplatin</intervention_name>
    <description>paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed infiltrating breast cancer.

          -  Stage II or stage III breast cancer.28 'Locally advanced breast cancer' patients are
             consequently eligible, including those with ipsilateral supraclavicular lymph node
             metastases. N1 status must have been demonstrated by either fine needle aspiration
             from an axillary lymph node or by a metastasis of &gt;2 mm in diameter at sentinel node
             biopsy. Stage IIA patients are eligible if the tumor is &gt;3 cm in diameter or if the
             tumor is between 2 and 3 cm in diameter but a breast conserving surgery is not
             possible.

          -  Overexpression and/or amplification of HER2 in an invasive component of the core
             biopsy, according to one of the following definitions:

               -  &gt;10% of invasive tumor cells showing strong complete circumferential membrane
                  staining (score 3+)

               -  &gt;10% of invasive tumor cells showing moderate complete circumferential membrane
                  staining (score 2+) and demonstrating HER2 gene amplification defined as a FISH
                  ratio of HER2 gene copies to chromosome 17 signals of &gt;2.2. or as &gt;5 HER2 gene
                  copies per nucleus in CISH analysis.

        Patients with a negative or equivocal overall result (FISH test ratio of &lt;2.2, &lt;6.0 HER2
        gene copies per nucleus) and staining scores of 0,1+, 2+ or 3+ (in 30% or less neoplastic
        cells) by IHC are not eligible for participation in the trial.

          -  Age ≥18

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤1 (Appendix B)

          -  Adequate bone marrow function (ANC &gt;1.0 x 109/l, platelets &gt;100 x 109/l)

          -  Adequate hepatic function (ALAT, ASAT and bilirubin &lt;2 times upper limit of normal)

          -  Adequate renal function (creatinine clearance &gt;60 ml/min)

          -  LVEF ≥50% measured by echocardiography or MUGA

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule

          -  Signed written informed consent

        Exclusion Criteria:

          -  No previous radiation therapy or chemotherapy

          -  No other malignancy except carcinoma in situ, unless the other malignancy was treated
             ≥5 years ago with curative intent without the use of chemotherapy or radiation
             therapy.

          -  No current pregnancy or breastfeeding. Women of childbearing potential must use
             adequate contraceptive protection.

          -  No evidence of distant metastases. Staging examinations must have included a chest
             radiograph, an ultrasound examination of the liver and an isotope bone scan. Abnormal
             uptake on the isotope bone scan can only be accepted if MRI, CT-scan, or plain
             radiograph excludes bone metastases.

          -  No concurrent anti-cancer treatment or another investigational drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G S Sonke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <zip>1800 AM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NKI-AVL</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <zip>2600 AG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5602 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennemer Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <zip>2035 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>Leidschendam</city>
        <zip>2262 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2008</study_first_submitted>
  <study_first_submitted_qc>October 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2008</study_first_posted>
  <last_update_submitted>May 10, 2012</last_update_submitted>
  <last_update_submitted_qc>May 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2012</last_update_posted>
  <responsible_party>
    <name_title>G.S. Sonke, MD PhD</name_title>
    <organization>NKI-AVL</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>neo-adjuvant</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>carboplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

